PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 3

Subgroup analysis of OS (PD-1/PD-L1 inhibitors vs. chemotherapy).

Subgroup	Total no. of studies	Total no. of patients	HR	95% CI
Histological type
SCC	4	1458	0.75	0.66∼0.84
ACC	2	872	1.00	0.86∼1.16
Tumor site
EC	4	1685	0.79	0.70∼0.88
GEJC	2	246	0.71	0.51∼1.00
GC	2	520	1.07	0.82∼1.40
Line
2	5	2186	0.82	0.73∼0.92
3∗	1	371	1.10	0.90∼1.40
PD-L1 expression status
Positive	5	1096	0.73	0.63∼0.84
Negative	4	890	1.000	0.81∼1.24
ECOG performance status
0	4	606	0.94	0.69∼1.28
1	4	1026	0.79	0.62∼1.02
Sex
Male	4	1217	0.83	0.73∼0.93
Female	4	316	0.84	0.51∼1.38
Age at baseline, years
<65	4	989	0.82	0.64∼1.05
≥65	4	644	0.83	0.70∼0.99
Region
Asia	6	1592	0.76	0.65∼0.88
Non-Asia	3	524	0.90	0.71∼1.16

Notes: ∗ The data of line 3 came from all the participants in the JAVELIN Gastric 300 study. This RCT focused on second-line and third-line applications, of which 86% were third-line applications.